Lyudmila A. Bazhenova, MD, discusses the PACIFIC study with durvalumab in stage III non–small-cell lung cancer.
Lyudmila A. Bazhenova, MD, medical oncologist, professor of clinical medicine, University of California, San Diego, discusses the PACIFIC study with durvalumab (Imfinzi) in stage III non–small-cell lung cancer (NSCLC).
The phase 3 PACIFIC trial was a randomized trial that enrolled patients with unresectable stage III NSCLC after completion of concurrent chemoradiation therapy, says Bazhenova. The type of radiation or chemotherapy patients were given was not prescribed by investigators from the PACIFIC study because that treatment was given prior to enrollment, explains Bazhenova. If the patient received chemoradiation therapy and did not progress, they were eligible for enrollment on the trial.
In the trial, patients were randomized 2:1 to receive either durvalumab every 2 weeks for 12 months versus placebo. Results from the study showed that durvalumab improved progression-free survival (PFS) as well as overall survival (OS), says Bazhenova. Specifically, preliminary results indicated that the median PFS was 16.8 months with durvalumab versus 5.6 months with placebo (HR, 0.52; 95% CI, 0.42-0.65; P < .0001). The 12-month PFS rate was 55.9% versus 35.3% with durvalumab versus placebo, respectively, and the 18-month PFS rate was 44.2% versus 27.0%, respectively. The median OS has not yet been reached in the durvalumab arm; however, consistent reports have demonstrated an improvement in OS at 12 months, 24 months, and 36 months, concludes Bazhenova.